ctDNA Monitoring in Lung Cancer: What It Can Tell You
Dr. Vrundali Kannoth|6 min read|
What Is ctDNA in Lung Cancer?
Circulating tumor DNA (ctDNA) are tiny fragments of genetic material released into the bloodstream by cancer cells. These fragments mix with cell-free DNA from normal cells.
As lung cancer cells grow or break down, they release DNA into nearby blood vessels. This ctDNA can hold genetic changes, such as mutations typical of the tumor.
What Is ctDNA Testing and How Does It Work?
ctDNA testing—a type of liquid biopsy—analyzes blood samples for tumor-derived DNA. The process generally involves:
- Drawing blood (usually from the arm)
- Separating plasma from blood cells
- Extracting cell-free DNA from plasma
- Using advanced techniques like PCR or next-generation sequencing (NGS) to identify genetic mutations in relevant genes (e.g., EGFR, ALK, ROS1, KRAS)
The genes and methods tested depend on whether the goal is initial profiling, resistance detection, monitoring treatment response, or checking for recurrence.
What Information Does ctDNA Monitoring Offer?
ctDNA analysis in lung cancer can provide:
- •Detection of tumor-specific genomic alterations
- •Insight into treatment response
- •Identification of resistance mutations
- •Early clues about recurrence
Results should always be considered along with scans, clinical evaluation, and pathology
Detecting Genetic Alterations
ctDNA can pinpoint actionable mutations—essential for targeting therapies—especially in advanced non-small cell lung cancer (NSCLC), or when tissue testing isn’t feasible.
Monitoring Treatment Response
Shifts in ctDNA levels can reflect how well treatment is working. Decreasing ctDNA may suggest positive response, while persistent or rising levels could indicate ongoing tumor activity.
Detecting Resistance Mutations
Some genetic changes linked to resistance (e.g., EGFR T790M) can be found through ctDNA testing. Detection may guide next treatment steps, but a negative ctDNA does not always rule out resistance, and tissue testing may still be needed.
Surveillance for Recurrence
Monitoring after treatment can sometimes spot the return of tumor-derived DNA before it’s visible on scans. However, ctDNA is not a substitute for routine imaging and follow-up.
Role of ctDNA in Non-Small Cell Lung Cancer (NSCLC)
ctDNA testing is most used in advanced or metastatic NSCLC to guide choices when tumor tissue is unavailable or further testing is required at progression. For earlier-stage NSCLC, tissue testing is usually the first choice, though ctDNA may help in select cases.
ctDNA Monitoring After Treatment
After surgery, therapy, or radiation, ctDNA can be tracked for signs of remaining cancer or recurrence. A positive result may lead to closer observation, but on its own, it doesn’t confirm recurrence.
ctDNA in Early Detection
Using ctDNA for early lung cancer detection is being researched, but it faces hurdles: small tumors may not shed enough dna, risk of false negatives, and standard protocols are still being developed. For now, low-dose CT scans remain standard for high-risk groups.
Benefits and Limitations of ctDNA Monitoring
Potential Benefits:
- Minimally invasive—requires only a blood sample
- Useful when tumor tissue isn’t available
- May identify targetable mutations and resistance changes
- Helpful in monitoring treatment and recurrence
- Supports personalized, precision oncology care
Limitations:
- Not all cancers release enough DNA for detection
- Sensitivity depends on tumor stage, burden, and shedding rate
- Negative results may need confirmatory tissue testing
- Cannot entirely replace imaging or traditional diagnosis
- Interpretation requires expert clinical input
Key Takeaways
ctDNA is a promising type of liquid biopsy for molecular profiling and disease monitoring in lung cancer, especially advanced NSCLC.
NGS-based tests can analyze ctDNA for key mutations, but not all tests are the same.
ctDNA supports treatment decisions and follow-up, but it’s an adjunct to other tools—not a standalone test.
Questions
Frequently Asked Questions
How is a ctDNA test done?
A blood sample is collected, plasma is separated, DNA is extracted, and advanced tests are run to find tumor mutations.
Can ctDNA spot recurrence?
Yes, it can sometimes detect recurrence, but it’s not definitive—imaging and clinical review are still essential.
Can ctDNA identify treatment resistance?
In some cases, yes—certain mutations linked to resistance (like EGFR T790M) can be found.
Is ctDNA the same as a liquid biopsy?
ctDNA testing is a main type of liquid biopsy, but liquid biopsy also covers circulating tumor cells and proteins.
Can ctDNA detect minimal residual disease?
ctDNA can be used in select settings to check for molecular residual disease, but it doesn’t yet replace all standard follow-up methods.
Related Blogs
